Benign prostat hiperplazisinde cerrahi sonrası gündelik hayata dönmeyi etkileyen faktörler

Abstract

Amaç: Bu prospektif çalışmada transüretral prostat rezeksiyonu TURP sonrasında hastaların ne kadar sürede gündelik hayatlarına döndüklerini ve bu süreyi etkileyen faktörleri bulmayı amaçladık.Gereç ve Yöntemler: Aralık 2009 ile Mayıs 2010 tarihleri arasında kliniğimizde, benign prostat hiperplazisi BPH tanısı ile TURP yapılan 37 hasta çalışmaya alındı. Hastaların yaşları, semptom süreleri, uluslararası prostatik semptom skorları IPSS , maksimum idrar akım hızları Qmax , prostat hacimleri, rezidüel idrar miktarları, preoperatif ve postoperatif hemoglobin Hb değerleri, preoperatif sondalı olup olmama durumları, hastanede yatış , postoperatif sonda çekilme ve operasyon süreleri kaydedildi. Hastalar postoperatif 1. ayda kontrole çağrıldı. Yüz yüze görüşme sırasında hastalara normalde yaptığı gündelik aktivitelere ne zaman başladıkları soruldu ve hastalar gündelik hayata dönme sürelerine göre

Keywords

• Benign prostat hiperplazisi,gündelik hayat,transüretral prostat rezeksiyonu,yaşam kalitesi

The factors affecting the return to daily life after surgery in benign prostatic hyperplasia

Abstract

Objective: In this prospective study, we aimed to find how soon patients return to their daily lives after transurethral prostate resection TURP and to determine the factors that affect the amount of time.Material and Methods: Between December 2009 and May 2010, thirty seven patients who underwent TURP in our clinic with the diagnosis of BPH were included in the study. The ages, duration of symptoms, international prostatic symptom scores IPSS , maximum flow rates Qmax , prostatic volumes, postvoid residual urine volumes, preoperative and postoperative hemoglobin Hb values, preoperative catheterization statuses, lengths of hospitalization, catheter removal times after operation and operation lengths of patients were noted. The patients were examined at first month after operation and were asked how soon they had returned to their daily lives in a face to face interview. Regarding the amount of recovery time over or less than 7 days , the patients were divided into two groups. Groups were compared as to the pre/postoperative factors that may affect their recovery. Results: When we compared two groups, we found that pre and postoperative Hb levels and lengths of hospitalization were significantly different between two groups p=0.03, 0.01 and 0.03, respectively . The most important variable in logistic regression analysis by Beckward-Stepwise method was postoperative Hb level.Conclusion: Postoperative Hb level seemed to be the most important independent variable affecting the recovery time of TURP patients. So we think that maximum care should be given to peroperative bleeding

Keywords

• Benign prostatic hyperplasia,daily life,quality of life,transurethral resection of prostate

References

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The develop- ment of human benign prostatic hyperplasia with age. J Urol 1984; 132:474-479.
2. Levin RM, Monson FC, Haugaard N, Buttyan R, Hudson A, Roelofs M, Sartore S, et al. Genetic and cellular charac- teristics of bladder outlet obstruction. Urol Clin North Am 1995; 22:263-283.
3. Chapple CR. BHP Disease Management. Introduction and concluding remarks. Eur Urol 1999;36 Suppl 3:1-6.
4. Djavan B. Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient’s quality of life. Uro- logy 2003; 62:6-14.
5. Schulman CC. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by tre- atment. Urology 2003; 62:24-33.
6. Yu X, Elliott SP, Wilt TJ, McBean AM. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol 2008; 180:241-245; discussion 245.
7. Kaplan SA. Update on the american urological association guidelines for the treatment of benign prostatic hyperpla- sia. Rev Urol 2006; 8 Suppl 4:S10-17.
8. Cote RJ, Burke H, Schoenberg HW. Prediction of unusu- al postoperative results by urodynamic testing in benign prostatic hyperplasia. J Urol 1981; 125:690-692.

9. Kojima M, Inui E, Ochiai A, Naya Y, Kamoi K, Ukimura O, Watanabe H. Reversible change of bladder hypertrophy due to benign prostatic hyperplasia after surgical relief of obstruction. J Urol 1997; 158:89-93.
10. Nam JG CN. Evaluation of persistent lower urinary tract symptoms after transurethral resection of prostate. Korean J Urol 2003; 44:540-544.
11. Gregory N. Effect of higher hemoglobin levels on health- related quality of life parameters. Nephrol Nurs J 2003; 30:75-78.
12. Carson JL, Terrin ML, Jay M. Anemia and postoperative rehabilitation. Can J Anaesth 2003; 50:S60-64.
13. Fitzpatrick J: Minimally Invasive and Endoscopic Manage- ment of Benign Prostatic Hyperplasia. In: Wein AJ KL, No- vick AC, Partin AW, Peters AC, ed. Campbell-Walsh Uro- logy. 10th ed. Philadelphia: Saunders, an imprint of Elsevi- er Inc., 2012; 2655-2694.
14. Mamoulakis C, Trompetter M, de la Rosette J. Bipolar transurethral resection of the prostate: the ‘golden stan- dard’ reclaims its leading position. Curr Opin Urol 2009; 19:26-32.
15. Garraway WM, Kirby RS. Benign prostatic hyperplasia: ef- fects on quality of life and impact on treatment decisions. Urology 1994; 44:629-636.
16. M. OL. Tamsulosin demonstrates long-term efficacy on Multiple clinical and quality-of-life scoring systems. Eur Urol Suppl 2002; 1:106.
17. Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subt- ypes and lower urinary tract symptoms. Int J Urol 2008; 15:193-199.
18. Cambio AJ, Evans CP. Outcomes and quality of life issu- es in the pharmacological management of benign prostatic hyperplasia (BPH). Ther Clin Risk Manag 2007; 3:181-196.
19. Varkarakis J, Bartsch G, Horninger W. Long-term morbi- dity and mortality of transurethral prostatectomy: a 10- year follow-up. Prostate 2004; 58:248-251.
20. Hong JY, Yang SC, Ahn S, Kil HK. Preoperative comorbi- dities and relationship of comorbidities with postoperative complications in patients undergoing transurethral prosta- te resection. J Urol 2011; 185:1374-1378.
21. Onem Y, Terekeci H, Kucukardali Y, Sahan B, Solmazgul E, Senol MG, Nalbant S, et al. Albumin, hemoglobin, body mass index, cognitive and functional performance in el- derly persons living in nursing homes. Arch Gerontol Ge- riatr 2010; 50:56-59.
22. Cortesi E, Gascon P, Henry D, Littlewood T, Milroy R, Pronzato P, Reinhardt U, et al. Standard of care for cancer- related anemia: improving hemoglobin levels and quality of life. Oncology 2005; 68 Suppl 1:22-32.
23. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Os- terborg A, Repetto L, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43:258-270.
24. Tan A, Liao C, Mo Z, Cao Y. Meta-analysis of holmium la- ser enucleation versus transurethral resection of the pros- tate for symptomatic prostatic obstruction. Br J Surg 2007; 94:1201-1208.
25. Ozdal OL, Ozden C, Benli K, Gokkaya S, Bulut S, Memis A. Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized control- led study. Prostate Cancer Prostatic Dis 2005; 8:215-218.
26. Zong HT, Peng XX, Yang CC, Zhang Y. A systematic revi- ew of the effects and mechanisms of preoperative 5alpha- reductase inhibitors on intraoperative haemorrhage du- ring surgery for benign prostatic hyperplasia. Asian J And- rol 2011; 13:812-818.